<DOC>
	<DOCNO>NCT01503450</DOCNO>
	<brief_summary>The purpose study compare single oral dose bioequivalence olanzapine 5 mg OD tablets Zyprexa Zydis 5 mg tablet feed condition monitor adverse event ensure safety subject .</brief_summary>
	<brief_title>Bioequivalence Study Olanzapine Orally Disintegrating Tablets , 5 mg Under Fed Condition</brief_title>
	<detailed_description>An open label , balance , randomize , two treatment , two-sequence , two-period , single-dose , crossover comparative bioequivalence study Olanzapine 5 mg OD Tablets , Dr. Reddy 's Laboratories Limited Zyprexa Zydis 5 mg Tablets Cardinal Health healthy , human subject feed condition .</detailed_description>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Healthy human subject within age range 18 45 year Nonsmokers since least six month Willingness provide write informed consent participate study Bodymass index ≥18.5 kg/m2 ≤ 24.9 kg/m2 , body weight less 50 kg Absence significant disease clinically significant abnormal laboratory value laboratory evaluation , medical history physical examination screen Normal 12lead ECG one abnormality consider clinically insignificant Normal chest Xray PA view Comprehension nature purpose study compliance requirement protocol Female Subjects child bear potential practicing acceptable method birth control duration study judge investigator ( ) , condom , foam . Jellies , diaphragm , intrauterine device ( IUD ) , abstinence , postmenopausal least 1 year , surgically sterile ( bilateral tubal ligation . bilateral oophorectomy , hysterectomy perform subject Personal / family history allergy hypersensitivity olanzapine ally drug Past history anaphylaxis angioedema Any major illness past three month clinically significant ongoing chronic medical illness e.g . congestive heart failure , hepatitis , pancreatitis etc . Presence clinically significant abnormal value screen e.g . significant abnormality liver Function Test ( LFT ) , Renal ( kidney ) Function Test ( RFT ) , etc . Any cardiac , renal liver impairment , organ system impairment History seizure psychiatric disorder Presence disease marker HIV 1 2 , hepatitis Band C virus Consumption alcohol two year , consumption three alcoholic drink per day consumption alcohol within 48 hour prior dose study [ one drink equal one unit alcohol [ one glass Wine , half plnt boor , one measure ( one ounce ) spirit ) . Consumption xanthine contain derivative ( coffee , tea , cola drink . chocolate ) within 48 hour checkin period Use recreational drug history drug addiction Participation clinical trial within past 3 month Inaccessibility vein leave right arm Donation blood ( one unit 350 mL ) within 3 month prior receive first dose study medication Receipt prescription drug therapy within four week overthecounter ( OTC ) drug within two week prior receive first dose study medication repeat use drug Within last four week An unusual diet , whatever reason e.g . low sodium diet , two week prior receive medication subject 's participation study Consumption grapefruit contain food beverage within 7 day prior receive first dose study medication period Recent history dehydration diarrhea , vomit reason within period 24 hour prior study Female volunteer demonstrate positive pregnancy screen currently breastfeed Having occupation requirement drive vehicle operate complex machinery 21 day take drug period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>